ERBB2 and breast cancer: LncRNA MALAT1 increased the expression of DNMT1, DNMT3A and DNMT3B and inhibited the BRCA1 and PTEN expression, leading to regulating of herceptin sensitivity in HER2-positive breast cancer (Yang et al., 2021).